Spironolactone in patients with resistant hypertension;Respuesta antihipertensiva a la espironolactona en pacientes con hipertensión arterial refractaria

Medicina Clinica

Volumn 131, Issue 11, 2008, Pages 406-411

  Rodilla, Enrique ^a,b   Costa, José A ^a   Pérez Lahiguera, Francisco ^a,b   González, Carmen ^a   Pascual, José M ^a,c  

^a HOSPITAL DE SAGUNTO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Resistant hypertension; Spironolactone; Uncontrolled hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; RETROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG RESISTANCE; EVALUATION; FOLLOW UP; MIDDLE AGED; STATISTICAL MODEL; TIME;

AGED; ALDOSTERONE ANTAGONISTS; CONFIDENCE INTERVALS; DIABETES COMPLICATIONS; DIURETICS; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149250980     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13126215     Document Type: Article

References (39)

1. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al., Nacional Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
2. Guidelines Committee. 2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
3. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:1981-97 [fe de errores: JAMA. 2003; 289:178; 2004;291:2196].
4. Black H.R., Elliott W.J., Grandits G., Grambsch P., Lucente T., White W.B., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 289 (2003) 2073-2082
5. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
6. Kaplan N.M. Resistant hypertension. J Hypertens 23 (2005) 1441-1444
7. Park J., and Campese V. Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich) 9 1 Suppl 1 (2007) 7-12
8. Papadopoulos D.P., and Papademetriou V. Resistant hypertension: diagnosis and management. J Cardiovasc Pharmacol Ther 11 (2006) 113-118
9. Moser M., and Setaro J.F. Clinical practice. Resistant or difficult-to-control hipertensión. N Engl J Med 355 (2006) 385-392
10. Taler S.J. Treatment of resistant hypertension. Curr Hypertens Rep 7 (2005) 323-329
11. Ouzan J., Perault C., Lincoff A.M., Carré E., and Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15 (2002) 333-339
12. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
13. Saha C., Eckert G.J., Ambrosius W.T., Chun T.Y., Wagner M.A., Zhao Q., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46 (2005) 481-487
14. Calhoun D.A. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens 9 Suppl 1 (2007) 19-24
15. Petrie J.C., O'Brien E.T., Littler W.A., and De Swiet M. Recommendations on blood pressure measurement. Br Med J (Clin Res Ed) 293 (1986) 611-615
16. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
17. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 Suppl 1 (2003) 5-20
19. Chapman N., Dobson J., Wilson S., Dahlöf B., Sever P.S., Wedel H., et al., on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
20. Saha C., Eckert G.J., Ambrosius W.T., Chun T.Y., Wagner M.A., Zhao Q., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46 (2005) 481-487
21. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 (2004) 139-185
22. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., and Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
23. Sabio J.M., Mediavilla-García J.D., Jaén F., Fernández- Torres C., Aliaga L., and Jiménez-Alonso J. Hiperaldosteronismo primario: análisis de una serie de 54 pacientes. Med Clin (Barc) 124 (2005) 765-768
24. Gordon R.D., Stowasser M., Tunny T.J., Klemm S.A., and Rutherford J.C. High incidence of primary hyperal dosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 (1994) 315-318
25. Fardella C.E., Mosso L., Gómez-Sánchez C., Cortes P., Soto J., Gómez L., et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 (2000) 1863-1867
26. Schwartz G.L., Chapman A.B., Boerwinkle E., Kisabeth R.M., and Turner S.T. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 48 (2002) 1919-1923
27. Kaplan N.M. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 22 (2004) 863-869
28. Plouin P.F., and Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits?. Eur J Endocrinol 151 (2004) 305-308
29. Hatakyama H., Miyamori I., Fujita T., Takeda Y., Takeda R., and Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269 (1994) 24316-24320
30. Rocha R., and Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 970 (2002) 89-100
31. Blacher J., Amah G., Girerd X., Kheder A., Ben Mais H., London G.M., et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 10 (1997) 1326-1334
32. Gómez-Sánchez E.P., Zhou M., and Gómez-Sánchez C.E. Mineralocorticoids, salt and high blood pressure. Steroids 61 (1996) 184-188
33. Guglin M., Awad K.E., Polavaram L., and Vankayala H. Aldosterone antagonists: the most underutilized class of heart failure medications. Am J Cardiovasc Drugs 7 (2007) 75-79
34. Croom K.F., and Perry C.M. Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs 5 (2005) 51-69
35. Marín R., De la Sierra A., Armario P., Campo C., Banegas J.R., and Gorostidi M. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) Guía sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005. Med Clin (Barc) 125 (2005) 24-34
36. Calvo C., Hermida R.C., Ayala D.E., López J.E., Fernández J.R., Mojón A., et al. Efectos de la administración temporalizada de fármacos antihipertensivos en pacientes con hipertensión arterial resistente. Med Clin (Barc) 126 (2006) 364-372
37. Pascual J.M., Rodilla E., Miralles A., González C., and Redón J. Determinants of urinary albumin excretion reduction in essential hypertension: a long-term follow-up study. J Hypertens 24 (2006) 2277-2284
38. Pascual J.M., Rodilla E., González C., Pérez-Hoyos S., and Redón J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 45 (2005) 1125-1130
39. Redon J., Campos C., Narciso M.L., Rodicio J.L., Pascual J.M., and Ruilope L.M. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 31 (1998) 712-718